1. Home
  2. MKTW vs EVAX Comparison

MKTW vs EVAX Comparison

Compare MKTW & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MarketWise Inc.

MKTW

MarketWise Inc.

HOLD

Current Price

$17.58

Market Cap

39.7M

Sector

Technology

ML Signal

HOLD

EVAX

Evaxion Biotech

HOLD

Current Price

$4.35

Market Cap

31.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MKTW
EVAX
Founded
1999
2008
Country
United States
Denmark
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.7M
31.9M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
MKTW
EVAX
Price
$17.58
$4.35
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
$20.00
$11.67
AVG Volume (30 Days)
24.9K
30.9K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
10.33%
N/A
EPS Growth
1183.33
N/A
EPS
2.31
N/A
Revenue
$512,403,000.00
N/A
Revenue This Year
$1.52
N/A
Revenue Next Year
$4.55
$328.20
P/E Ratio
$7.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.65
$1.42
52 Week High
$21.74
$12.15

Technical Indicators

Market Signals
Indicator
MKTW
EVAX
Relative Strength Index (RSI) 55.90 52.07
Support Level $16.06 $2.64
Resistance Level $20.62 $4.62
Average True Range (ATR) 0.87 0.32
MACD -0.04 -0.02
Stochastic Oscillator 77.84 30.71

Price Performance

Historical Comparison
MKTW
EVAX

About MKTW MarketWise Inc.

Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms, including mobile, desktop, and tablets.

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

Share on Social Networks: